1.64
price down icon2.96%   -0.05
after-market  アフターアワーズ:  1.64 
loading

Oragenics Inc (OGEN) 最新ニュース

Oragenics (NYSE:OGEN) Research Coverage Started at StockNews.com - Defense World

pulisher
Defense World

StockNews.com Initiates Coverage on Oragenics (NYSE:OGEN) - Defense World

pulisher
Defense World

Closing Bell Recap: Oragenics Inc (OGEN) Ends at 2.04, Reflecting a 3.55 Upturn – DWinneX - The Dwinnex

pulisher
The Dwinnex

Oragenics (NYSE:OGEN) Research Coverage Started at StockNews.com - Defense World

pulisher
Defense World

Ratio Examination: Oragenics Inc (OGEN)'s Price-to-Cash and Price-to-Free Cash Flow – DWinneX - The Dwinnex

pulisher
The Dwinnex

Oragenics names new Chief Clinical Officer By Investing.com - Investing.com Canada

pulisher
Investing.com Canada

Oragenics Appoints William “Frank” Peacock MD As Chief Clinical Officer - citybiz

pulisher
citybiz

Oragenics names new Chief Clinical Officer By Investing.com - Investing.com Australia

pulisher
Investing.com Australia

Oragenics names new Chief Clinical Officer By Investing.com - Investing.com

pulisher
Investing.com

Oragenics names new Chief Clinical Officer By Investing.com - Investing.com UK

pulisher
Investing.com UK

Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer - GlobeNewswire

pulisher
GlobeNewswire

Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer - Yahoo Finance

pulisher
Yahoo Finance

Holdings of Oragenics Inc (OGEN) are aligned with the stars – Sete News - SETE News

pulisher
SETE News

ImmunityBio (NASDAQ: IBRX) Advances in Oncology: Gearing Up for ANKTIVA's Commercial Rollout - BP Journal

pulisher
BP Journal

StockNews.com Begins Coverage on Oragenics (NYSE:OGEN) - Defense World

pulisher
Defense World

StockNews.com Begins Coverage on Oragenics (NYSE:OGEN) - Defense World

pulisher
Defense World

Oragenics prepares ONP-002 for Phase II concussion trial - TipRanks.com - TipRanks

pulisher
TipRanks

Oragenics, Inc (NYSE: OGEN) Surges 34% Amidst Webinar Announcement and Intranasal Pharmaceutical Development - BP Journal

pulisher
BP Journal

Nuburu Inc (NYSE: BURU) Surges Amid Exciting Developments - BP Journal

pulisher
BP Journal

Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine - GlobeNewswire

pulisher
GlobeNewswire

Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine - Markets Insider

pulisher
Markets Insider

Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine - GlobeNewswire

pulisher
GlobeNewswire

Oragenics climbs 9% amid Phase 2 study, business updates - MSN

pulisher
MSN

Oragenics climbs 9% amid Phase 2 study, business updates (NYSE:OGEN) - Seeking Alpha

pulisher
Seeking Alpha

Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial - GlobeNewswire

pulisher
GlobeNewswire

Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial - Markets Insider

pulisher
Markets Insider

Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial - Yahoo Finance

pulisher
Yahoo Finance

Oragenics: Q1 Earnings Snapshot | Business | valdostadailytimes.com - Valdosta Daily Times

pulisher
Valdosta Daily Times

Oragenics: Q1 Earnings Snapshot | Business | valdostadailytimes.com - Valdosta Daily Times

pulisher
Valdosta Daily Times

Oragenics Inc. to Present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference - The Globe and Mail

pulisher
The Globe and Mail

Oragenics, Inc. Announces New Chair - The Globe and Mail

pulisher
The Globe and Mail

SARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Demonstrates Protective Immunity in Mice - The Globe and Mail

pulisher
The Globe and Mail

Oragenics, Inc. Announces $6.5 Million Registered Direct Offering - The Globe and Mail

pulisher
The Globe and Mail

Oragenics to Participate in the World Vaccine Congress Washington - The Globe and Mail

pulisher
The Globe and Mail

Oragenics Signs Process Development and Manufacturing Agreement With Avid Bioservices for Coronavirus Vaccine - The Globe and Mail

pulisher
The Globe and Mail

StockNews.com Begins Coverage on Oragenics (NYSE:OGEN) - Defense World

pulisher
Defense World

Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia - Markets Insider

pulisher
Markets Insider

Oragenics Inc Reports SEC Filing Update - TipRanks.com - TipRanks

pulisher
TipRanks

Oragenics partners with Avance Clinical for Phase 2 concussion study (NYSE:OGEN) - Seeking Alpha

pulisher
Seeking Alpha

Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia - GlobeNewswire

pulisher
GlobeNewswire

Oragenics Inc Reports SEC Filing Update - TipRanks

pulisher
TipRanks

StockNews.com Begins Coverage on Oragenics (NYSE:OGEN) - Defense World

pulisher
Defense World

StockNews.com Begins Coverage on Oragenics (NYSE:OGEN) - Defense World

pulisher
Defense World

Sarasota biotech company noncompliant with NYSE listing standards - Business Observer

pulisher
Business Observer

Oragenics advances with new neurological treatment platform - Investing.com ZA - Investing.com South Africa

pulisher
Investing.com South Africa

Oragenics Announces Closing of Public Offering - Business Wire

pulisher
Business Wire

S&P 500 Edges Lower; ADT Posts Upbeat Earnings

pulisher
Benzinga

Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

pulisher
Benzinga

Nasdaq Down 50 Points; US Crude Stocks Rise By 4.2M Barrels

pulisher
Benzinga

Dow Dips 200 Points; TJX Posts Upbeat Sales

pulisher
Benzinga
$83.51
price down icon 0.87%
$26.19
price down icon 0.83%
$162.58
price down icon 2.28%
$160.39
price up icon 0.21%
$92.08
price down icon 4.08%
$387.00
price down icon 0.35%
大文字化:     |  ボリューム (24 時間):